CRISPR Therapeutics (NASDAQ:CRSP) Hits New 12-Month Low - What's Next?

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $36.70 and last traded at $37.04, with a volume of 992191 shares. The stock had previously closed at $39.69.

Analyst Upgrades and Downgrades

CRSP has been the subject of a number of analyst reports. Royal Bank of Canada restated a "sector perform" rating and set a $53.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. StockNews.com raised shares of CRISPR Therapeutics to a "sell" rating in a report on Monday, December 30th. Chardan Capital reaffirmed a "buy" rating and issued a $94.00 price objective on shares of CRISPR Therapeutics in a report on Tuesday, December 10th. Needham & Company LLC reissued a "buy" rating and set a $84.00 target price on shares of CRISPR Therapeutics in a research note on Tuesday. Finally, Bank of America decreased their target price on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating for the company in a research report on Tuesday, January 7th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $78.38.

CRISPR Therapeutics Stock Up 1.8 %

The company has a 50 day moving average of $45.46 and a two-hundred day moving average of $48.30. The firm has a market cap of $3.33 billion, a P/E ratio of -13.80 and a beta of 1.62.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The company had revenue of $0.60 million during the quarter, compared to analyst estimates of $6.65 million. During the same quarter last year, the firm posted ($1.41) EPS. Research analysts expect that CRISPR Therapeutics AG will post -5.13 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Samarth Kulkarni sold 15,000 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total transaction of $826,500.00. Following the completion of the sale, the chief executive officer now owns 181,540 shares in the company, valued at approximately $10,002,854. This represents a 7.63 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Itau Unibanco Holding S.A. purchased a new position in CRISPR Therapeutics in the 2nd quarter worth about $35,000. Highline Wealth Partners LLC acquired a new position in shares of CRISPR Therapeutics in the fourth quarter worth about $39,000. Wilmington Savings Fund Society FSB purchased a new position in shares of CRISPR Therapeutics in the third quarter worth approximately $40,000. Darwin Wealth Management LLC acquired a new stake in shares of CRISPR Therapeutics during the third quarter valued at approximately $43,000. Finally, Elkhorn Partners Limited Partnership purchased a new stake in shares of CRISPR Therapeutics in the 2nd quarter valued at approximately $54,000. 69.20% of the stock is owned by institutional investors and hedge funds.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.